Arcturus Therapeutics (NASDAQ:ARCT) Price Target Raised to $19.00

Posted by Geri Gentry on Oct 12th, 2026

Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price target boosted by Leerink Partners from $13.00 to $19.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

ARCT has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Thursday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Citigroup raised Arcturus Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $8.00 to $20.00 in a research report on Thursday, September 24th. Finally, Roth Capital reissued a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.00.

Read Our Latest Analysis on Arcturus Therapeutics

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $13.74 on Friday. The company has a market cap of $390.49 million, a price-to-earnings ratio of -4.15 and a beta of 2.48. Arcturus Therapeutics has a twelve month low of $5.50 and a twelve month high of $24.17. The company has a 50 day moving average of $12.75 and a two-hundred day moving average of $9.31.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.16. The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, sell-side analysts expect that Arcturus Therapeutics will post -3.48 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ARCT. Versant Capital Management Inc lifted its stake in shares of Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock worth $42,000 after buying an additional 2,627 shares during the period. Two Sigma Securities LLC purchased a new stake in shares of Arcturus Therapeutics during the second quarter valued at $80,000. ADAR1 Capital Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $116,000. Diversify Wealth Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $133,000. Finally, Diversify Advisory Services LLC acquired a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at $91,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

(Get Free Report)

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.